tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Myelitis D009187 1 associated lipids
Erythroplasia D004919 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Hutchinson's Melanotic Freckle D018327 2 associated lipids
Lacerations D022125 1 associated lipids
Trauma, Nervous System D020196 2 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Arm Injuries D001134 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Lee YJ et al. Acquired Bilateral Dyspigmentation on Face and Neck: Clinically Appropriate Approaches. 2016 J. Korean Med. Sci. pmid:27822947
Khan S et al. Tacrolimus-loaded nanostructured lipid carriers for oral delivery - Optimization of production and characterization. 2016 Eur J Pharm Biopharm pmid:27449630
Siponen M et al. Cathepsin K expression is increased in oral lichen planus. 2016 J. Oral Pathol. Med. pmid:27152719
Tomei P et al. Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation. 2016 J. Nephrol. pmid:27026415
Chitvanich S et al. Combination of non-ablative fractional photothermolysis and 0.1% tacrolimus ointment is efficacious for treating idiopathic guttate hypomelanosis. 2016 J Dermatolog Treat pmid:26864301
Klein OR et al. Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders. 2016 Biol. Blood Marrow Transplant. pmid:26860634
Ishida H et al. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial. 2016 Exp Clin Transplant pmid:27733107
Tsunashima D et al. Preparation of extended release solid dispersion formulations of tacrolimus using ethylcellulose and hydroxypropylmethylcellulose by solvent evaporation method. 2016 J. Pharm. Pharmacol. pmid:26773717
Mok MM et al. Acute Phosphate Nephropathy: An Under-Recognized Complication Leading to Impaired Allograft Function After Renal Transplant. 2016 Nephrology (Carlton) pmid:27730726
Stocki P et al. Inhibition of the FKBP family of peptidyl prolyl isomerases induces abortive translocation and degradation of the cellular prion protein. 2016 Mol. Biol. Cell pmid:26764098
Bogossian H et al. Expression of NO Synthase Under Medication with Cyclosporine A, Mycophenolate Mofetil, and Tacrolimus during Development of Transplant Vasculopathy on Rat Cardiac Allograft. 2016 Cardiovasc Ther pmid:26924260
Michael M et al. Outcomes of two-drug maintenance immunosuppression for pediatric renal transplantation: 10-yr follow-up in a single center. 2016 Pediatr Transplant pmid:26916966
Treister N et al. An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. 2016 Biol. Blood Marrow Transplant. pmid:27590106
Jun H et al. Clinical advantages including medication adherence with conversion to once-daily advagraf and sirolimus combination in stable kidney recipients. 2016 Int J Clin Pharmacol Ther pmid:26709601
Schmutz JL [No increased risk of cancer under pimecrolimus]. 2016 Ann Dermatol Venereol pmid:26708204
Valbuena H et al. Comparing the effect of isotopically labeled or structural analog internal standards on the performance of a LC-MS/MS method to determine ciclosporin A, everolimus, sirolimus and tacrolimus in whole blood. 2016 Clin. Chem. Lab. Med. pmid:26351941
Kronbichler A et al. Moderator's view: The use of calcineurin inhibitors in the treatment of lupus nephritis. 2016 Nephrol. Dial. Transplant. pmid:27591329
Juvvadi PR et al. Novel motif in calcineurin catalytic subunit is required for septal localization of calcineurin in Aspergillus fumigatus. 2016 FEBS Lett. pmid:26864964
Wang L et al. Therapeutic advances for primary biliary cholangitis: the old and the new. 2016 Eur J Gastroenterol Hepatol pmid:26862931
Ben Fredj N et al. Modeling of Tacrolimus Exposure in Kidney Transplant According to Posttransplant Time Based on Routine Trough Concentration Data. 2016 Exp Clin Transplant pmid:27506258
Miyata Y et al. Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms. 2016 Ann. Transplant. pmid:27503662
Hirsch HH et al. BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12. 2016 Am. J. Transplant. pmid:26639422
Griffin SP and Nelson JE Impact of a Clinical Solid Organ Transplant Pharmacist on Tacrolimus Nephrotoxicity, Therapeutic Drug Monitoring, and Institutional Revenue Generation in Adult Kidney Transplant Recipients. 2016 Prog Transplant pmid:27628498
Faraj W et al. Osteoporosis in Pediatric Liver Transplantation. 2016 Prog Transplant pmid:27555069
Saliba F et al. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study. 2016 Transplantation pmid:27454919
Liu XX et al. Limited Sampling Strategy for the Estimation of Tacrolimus Area Under the Concentration-Time Curve in Chinese Adult Liver Transplant Patients. 2016 Pharmacology pmid:27449772
Chan SW et al. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. 2016 J Clin Pharm Ther pmid:27511886
Gastaca M et al. Favorable longterm outcomes of liver transplant recipients treated de novo with once-daily tacrolimus: Results of a single-center cohort. 2016 Liver Transpl. pmid:27434676
Qi XM et al. FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats. 2016 Inflamm. Res. pmid:26566632
Seo J et al. Therapeutic advantage of inhaled tacrolimus-bound albumin nanoparticles in a bleomycin-induced pulmonary fibrosis mouse model. 2016 Pulm Pharmacol Ther pmid:26768967
Zhang X et al. The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis. 2016 Int Urol Nephrol pmid:26781720
Ayyala RS et al. Imaging findings in a child with calcineurin inhibitor-induced pain syndrome after bone marrow transplant for beta thalassemia major. 2016 Pediatr Radiol pmid:27324395
Miura K et al. Development of the Intestinal Transplantation Model With Major Histocompatibility Complex Inbred CLAWN Miniature Swine. 2016 Transplant. Proc. pmid:27320612
Lien YH Top 10 Things Primary Care Physicians Should Know About Maintenance Immunosuppression for Transplant Recipients. 2016 Am. J. Med. pmid:26714210
Wilkes SR et al. How Clinically Relevant Are Treatment Comparisons of Topical Calcineurin Inhibitor Trials for Atopic Eczema? 2016 J. Invest. Dermatol. pmid:27265005
Miura M et al. Inter-laboratory Variability of Current Immunoassay Methods for Tacrolimus among Japanese Hospitals. 2016 Biol. Pharm. Bull. pmid:27263473
Weiner SM [Combination of tacrolimus and MMF for treatment of proliferative lupus nephritis]. 2016 Z Rheumatol pmid:27259912
Gaynor JJ et al. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. 2016 Transpl. Int. pmid:26442829
Hannun P et al. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. 2016 Ther Drug Monit pmid:26919549
Medeiros M et al. Are Tacrolimus Pharmacokinetics Affected by Nephrotic Stage? 2016 Ther Drug Monit pmid:27167176
Nijhoff MF et al. Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression. 2016 Am. J. Transplant. pmid:26288226
Otte JB Pediatric liver transplantation: Personal perspectives on historical achievements and future challenges. 2016 Liver Transpl. pmid:27096329
Anuradha D and Parsad FK506 regulates pigmentation by maturing the melanosome and facilitating their transfer to keratinocytes. 2016 Dermatol Ther pmid:27093927
Krejci K et al. Clinical experience of conversion from cyclosporine to tacrolimus prolonged-release in stabilized kidney transplant patients. 2016 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub pmid:27174195
Muduma G et al. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. 2016 J Med Econ pmid:27172118
Tariciotti L et al. Everolimus and Advagraf Ab Initio in Combined Liver and Kidney Transplant With Donor-Specific Antibodies: A Case Report. 2016 Transplant. Proc. pmid:27932158
Alagoz S et al. Gangliocytoma Presenting With Tacrolimus Neurotoxicity in a Renal Transplant Recipient: Case Report. 2016 Transplant. Proc. pmid:27932167
Wakamatsu A et al. Role of calcineurin (CN) in kidney glomerular podocyte: CN inhibitor ameliorated proteinuria by inhibiting the redistribution of CN at the slit diaphragm. 2016 Physiol Rep pmid:27009276
Sugitani A et al. Unusual case of tacrolimus vascular toxicity after deceased donor renal transplantation. 2016 Nephrology (Carlton) pmid:27004749
Oddis CV Update on the pharmacological treatment of adult myositis. 2016 J. Intern. Med. pmid:27098592